In a table (Table 2), we outline several compounds that have a suppressive effect against the activation of NLRP3 inflammasome and, therefore, can represent the protagonists of the new frontiers of pharmacological therapy of ischemic stroke. This evidence concerns the gene NLRP3 and ischemic stroke.